HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Martek Plans 2011 Supplement Launches Through Amerifit Subsidiary

This article was originally published in The Tan Sheet

Executive Summary

Martek Biosciences' dietary supplement pipeline comes into focus as the developer of algae-based omega-3 oils lines up a slate of products to launch in 2011 through its Amerifit Brands business

You may also be interested in...

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2010

During the fourth quarter of 2010, 86 biopharmaceutical financings totalled $5.73 billion altogether, a whopping 239% increase over the previous three-month period in which 71 deals garnered $1.69 billion. M&A dollar volume also increased - 20 acquisitions brought in a combined $9.4 billion, a large chunk of which was Pfizer's $3.56 billion buy of King. And alliances between universities and biopharma companies, particularly Big Pharma and start-ups, were abundant.

DSM's $1.1B Martek Acquisition Comes With Potential IP Expirations

Dutch ingredients giant Royal DSM N.V. incurs no incremental risk in acquiring Martek Biosciences despite the looming expiration dates for Martek's intellectual property, according to a market analyst.

Martek plans offsets for formula contracts

Martek Biosciences CEO Steve Dubin says the nutritional oils firm will offset price reductions in extended infant formula supply contracts with Mead Johnson and Danone through formula market growth, new production technologies and expansion of its Amerifit Brands business. Dubin said during an earnings call Sept. 1 that Amerifit will launch five to seven supplement stock-keeping units in 2011 (1"The Tan Sheet" Aug. 16, 2010). Martek reported cost reductions in life'sDHA and life'sARA production, and efficiencies from Amerifit - acquired in January - helped swell its third-quarter gross margin to nearly 50 percent from 44 percent in the year-ago period. Dubin said he expects further margin, revenue and earnings growth in 2011. The Columbia, Md.-based firm recorded net sales of $114 million in the May-July timeframe, a 51.9 percent increase

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts